Watson buys rights to visual cervical screen
This article was originally published in Clinica
Executive Summary
Watson Pharmaceuticals has bought the US product rights to a visual cervical screening product from Trylon for an undisclosed amount. Corona, California-based Watson, a specialty pharmaceutical company, says the deal will augment its offerings to women's health practitioners.